| Lead-Like | Fragment-Like | Drug-Like | All | Shards | |
|---|---|---|---|---|---|
| Standard Size Updated | Lead-Like 5,288,491 2012-01-31 | Fragment-Like 562,227 2012-02-03 | Drug-Like 14,322,885 2012-01-12 | All Purchasable 19,734,523 2012-01-12 | Shards 52,189 2012-02-02 |
| Clean Size Updated | Clean Leads 2,722,829 2011-12-19 | Clean Fragments 281,766 2011-12-16 | Clean Drug-Like 9,928,465 2011-12-25 | All Clean 11,085,556 2012-01-02 | Clean Shards 20,125 2011-12-15 |
| In Stock Size Updated | Leads Now 1,812,189 2011-12-21 | Frags Now 385,125 2012-02-03 | Drugs Now 6,189,845 2012-01-02 | All Now 12,077,637 2011-12-16 | Shards Now 47,531 2012-01-02 |
Comments/Citation |
Teague, Davis, Leeson, Oprea, Angew Chem Int Ed Engl. 1999 Dec 16;38(24):3743-3748.
|
Carr RA, Congreve M, Murray CW, Rees DC, Drug Discov Today. 2005 Jul 15;10(14):987
|
Lipinski, J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49.
|
Purchasable chemical space
|
Type I binding sites
|
Filtering Critieria |
(p.xlogp < 3.5 and p.mwt < 350 and p.rb <= 7) and not (p.xlogp <=2.5 and p.mwt <=250 and p.rb <= 5)
|
p.xlogp <=3.5 and p.mwt <=250 and p.rb <= 5
|
p.xlogp <= 5 and p.mwt <= 500 and p.mwt > 150 and p.rb < 8 and p.psa < 150 and p.n_h_acceptors <= 10
|
|
p.mwt < 160
|